Dahili, Fe B.

HRN: 29-02-62  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/20/2026
CO-AMOXICLAV 625MG (TAB)
05/20/2026
05/27/2026
PO
625MG
BID
LACERATED WOUND HEAD AND EAR
Pending Pharmacy Acceptance 

 Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: